论文部分内容阅读
智利伊基克1982年发生B群脑膜炎球菌疾病爆发,到1987年发病率比智利基础发病率约高20倍。本文报道了在伊基克进行的一项前瞻性随机对照现场试验的结果,评价了B群外膜蛋白菌苗的保护效力。 作者在伊基克及近郊挑选了年龄1～21岁的居民万余人,分成两组:实验组20617人;对照组20177人。实验菌苗为流行株8529(B∶15∶P1.3∶L3.7)经两性离子去污剂EmpigenBB纯化其外膜蛋白后,与C群荚膜多糖形成的非共价复合物,用氢氧化铝吸附。对照菌苗为批准的A、C、Y和W135群脑膜炎球菌荚膜多糖菌苗。用喷射器分别在0和6周接种,
The outbreak of serogroup B meningococcal disease occurred in 1982 in Iquique, Chile. By 1987, the incidence was about 20 times higher than the basic incidence in Chile. This article reports the results of a prospective randomized controlled field trial conducted in Iquique to evaluate the protective efficacy of the outer membrane protein vaccine of group B. In Iquique and the outskirts, the authors selected more than 10,000 residents aged 1 to 21 years old and divided them into two groups: 20,617 in the experimental group and 2,0177 in the control group. Experimental vaccine for the epidemic strain 8529 (B: 15: P1.3: L3.7) After the zwitterionic detergent EmpigenBB purification of its outer membrane protein, with the group C capsular polysaccharide formation of non-covalent complex with hydrogen Alumina adsorption. Control bacterins were approved groups A, C, Y and W135 meningococcal capsular polysaccharide vaccine. Vaccines were vaccinated at 0 and 6 weeks respectively,